These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31913266)

  • 1. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
    Arriazu E; Vicente C; Pippa R; Peris I; Martínez-Balsalobre E; García-Ramírez P; Marcotegui N; Igea A; Alignani D; Rifón J; Mateos MC; Cayuela ML; Nebreda AR; Odero MD
    Blood Cancer J; 2020 Jan; 10(1):3. PubMed ID: 31913266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
    Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
    Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
    Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
    Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM
    Oncotarget; 2016 Jul; 7(30):47465-47478. PubMed ID: 27329844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
    Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
    J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
    Cristóbal I; Garcia-Orti L; Cirauqui C; Cortes-Lavaud X; García-Sánchez MA; Calasanz MJ; Odero MD
    Haematologica; 2012 Apr; 97(4):543-50. PubMed ID: 22133779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
    Arriazu E; Pippa R; Odero MD
    Front Oncol; 2016; 6():78. PubMed ID: 27092295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
    Zonta F; Pagano MA; Trentin L; Tibaldi E; Frezzato F; Trimarco V; Facco M; Zagotto G; Pavan V; Ribaudo G; Bordin L; Semenzato G; Brunati AM
    Blood; 2015 Jun; 125(24):3747-55. PubMed ID: 25931585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
    Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
    Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
    Yang Y; Huang Q; Lu Y; Li X; Huang S
    J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of PP2A activator on proliferation of HL-60 cells and analysis of PP2A activity changes in patients with acute myeloid leukemia].
    Yang Y; Li XQ; Huang Q; Huang SA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):594-7. PubMed ID: 21729530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.
    Shouse G; de Necochea-Campion R; Mirshahidi S; Liu X; Chen CS
    Oncotarget; 2016 Sep; 7(38):61081-61092. PubMed ID: 27531894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
    Goswami S; Mani R; Nunes J; Chiang CL; Zapolnik K; Hu E; Frissora F; Mo X; Walker LA; Yan P; Bundschuh R; Beaver L; Devine R; Tsai YT; Ventura A; Xie Z; Chen M; Lapalombella R; Walker A; Mims A; Larkin K; Grieselhuber N; Bennett C; Phelps M; Hertlein E; Behbehani G; Vasu S; Byrd JC; Muthusamy N
    Blood; 2022 Mar; 139(9):1340-1358. PubMed ID: 34788382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses.
    Wu SY; Wen YC; Ku CC; Yang YC; Chow JM; Yang SF; Lee WJ; Chien MH
    J Biomed Sci; 2019 Aug; 26(1):63. PubMed ID: 31470848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.
    Ruvolo PP; Qui YH; Coombes KR; Zhang N; Ruvolo VR; Borthakur G; Konopleva M; Andreeff M; Kornblau SM
    Leukemia; 2011 Nov; 25(11):1711-7. PubMed ID: 21660042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.